Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Daily for 28 Days to Patients With Advanced Solid Tumors

Trial Profile

A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Daily for 28 Days to Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs TP 0184 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Tolero Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2018 According to a Tolero Pharmaceuticals media release, first patients has been dosed in this study.
    • 25 Jul 2018 Status changed from not yet recruiting to recruiting, according to a Tolero Pharmaceuticals media release.
    • 14 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top